Edgewise Therapeutics, Inc. (EWTX)

Edgewise Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	61.15	41.67	86.1	21.99	15.57
Short-Term Investments	468.96	428.5	232.3	329.95	265.22
Cash & Short-Term Investments	530.11	470.17	318.39	351.95	280.79
Cash Growth	12.75%	47.67%	-9.53%	25.34%	117.51%
Other Current Assets	13.28	5.31	8.6	5.05	2.98
Total Current Assets	543.39	475.48	327	357	283.77
Net Property, Plant & Equipment	9.22	11.07	12.69	9.85	0.91
Other Long-Term Assets	-	0.26	0.35	0.25	0.55
Total Assets	552.6	486.82	340.04	367.1	285.23
Accounts Payable	6.01	5.58	4.03	6.11	3.84
Accrued Expenses	20.35	17.29	11.77	9.87	6.68
Current Portion of Leases	1.01	1	0.98	0.61	-
Total Current Liabilities	27.37	23.86	16.77	16.59	10.52
Long-Term Leases	2.98	3.74	4.43	3.8	-
Other Long-Term Liabilities	-	-	-	-	0.33
Total Long-Term Liabilities	2.98	3.74	4.43	3.8	0.33
Total Liabilities	30.35	27.6	21.21	20.39	10.85
Common Stock	0.01	0.01	0.01	0.01	0.01
Additional Paid-in Capital	1,068	837.36	563.49	492.67	351.85
Accumulated Other Comprehensive Income	0.68	0.42	0.1	-1.36	-0.51
Retained Earnings	-546.37	-378.58	-244.76	-144.6	-76.96
Total Common Shareholders' Equity	522.26	459.22	318.83	346.72	274.38
Shareholders' Equity	522.26	459.22	318.83	346.72	274.38
Total Liabilities & Equity	552.6	486.82	340.04	367.1	285.23
Total Debt	3.99	4.74	5.41	4.41	0
Net Cash (Debt)	526.12	465.43	312.98	347.54	280.79
Net Cash Growth	13.04%	48.71%	-9.94%	23.77%	117.51%
Net Cash Per Share	5.11	5.04	4.91	6.49	7.48
Book Value	522.26	459.22	318.83	346.72	274.38
Book Value Per Share	5.07	4.97	5.00	6.47	7.31
Tangible Book Value	522.26	459.22	318.83	346.72	274.38
Tangible Book Value Per Share	5.07	4.97	5.00	6.47	7.31

Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q